With this in mind, they tested Y-27632, a selective inhibitor of a recently identified kinase, p160-Rho-associated coiled-coil kinase (ROCK). Upon treatment with this compound, dissociation ...

CPL 409116 is the first in class dual JAK/ROCK inhibitor in clinical development and is designed to generate anti-inflammatory and anti-fibrotic effects in selected autoimmune diseases.

Leveraging advanced spatial proteomics, scientists have identified the JAK/STAT pathway as a critical target ... researchers ...